In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...
As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO ...
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has ...
True lab orchestration isn't about coordinating instruments, it's about connecting scientific intent, data, and decisions ...
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination ...
In today's ACT Brief, we examine why black-box AI fails in clinical trials, how participant understanding drives engagement ...
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
Why clinical development’s next AI bottleneck is not the model, but the system around it. “An AI-enabled workflow should identify the downstream implications of a change, propose aligned updates, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results